B-intervention	0	13	Perioperative
I-intervention	14	25	intravenous
I-intervention	26	35	lidocaine
O	36	45	decreases
O	46	49	the
B-condition	50	59	incidence
I-condition	60	62	of
I-condition	63	73	persistent
I-condition	74	78	pain
O	79	84	after
O	85	91	breast
O	92	99	surgery
O	99	100	.

O	101	107	Breast
O	108	114	cancer
O	115	122	surgery
O	123	125	is
O	126	136	associated
O	137	141	with
O	142	143	a
O	144	148	high
O	149	158	incidence
O	159	161	of
B-condition	162	172	persistent
I-condition	173	185	postsurgical
I-condition	186	190	pain
I-condition	191	192	(
I-condition	192	196	PPSP
I-condition	196	197	)
O	197	198	.

O	199	202	The
O	203	206	aim
O	207	209	of
O	210	214	this
O	215	220	study
O	221	224	was
O	225	227	to
O	228	236	evaluate
O	237	240	the
O	241	247	impact
O	248	250	of
O	251	262	intravenous
O	263	264	(
O	264	266	IV
O	266	267	)
O	268	277	lidocaine
O	278	280	on
O	281	286	acute
O	287	290	and
O	291	295	PPSP
O	295	296	,
O	297	306	analgesic
O	307	319	requirements
O	319	320	,
O	321	324	and
O	325	334	sensation
O	335	348	abnormalities
O	349	351	in
O	352	360	patients
O	361	371	undergoing
O	372	379	surgery
O	380	383	for
O	384	390	breast
O	391	397	cancer
O	397	398	.

B-total-participants	399	405	Thirty
I-total-participants	405	406	-
I-total-participants	406	409	six
O	410	418	patients
O	419	431	participated
O	432	434	in
O	435	439	this
O	440	450	randomized
O	450	451	,
O	452	458	double
O	458	459	-
O	459	466	blinded
O	467	472	study
O	472	473	.

O	474	480	Before
O	481	490	induction
O	491	493	of
O	494	501	general
O	502	512	anesthesia
O	512	513	,
O	514	522	patients
O	523	531	received
O	532	533	a
O	534	539	bolus
O	540	542	of
O	543	554	intravenous
O	555	564	lidocaine
O	565	566	1
O	566	567	.
O	567	568	5
O	569	571	mg
O	571	572	/
O	572	574	kg
O	575	583	followed
O	584	586	by
O	587	588	a
O	589	599	continuous
O	600	608	infusion
O	609	611	of
O	612	621	lidocaine
O	622	623	1
O	623	624	.
O	624	625	5
O	626	628	mg
O	628	629	/
O	629	632	kgh
O	633	634	(
O	634	643	lidocaine
O	644	649	group
O	649	650	)
O	651	653	or
O	654	656	an
O	657	662	equal
O	663	669	volume
O	670	672	of
B-control	673	679	saline
I-control	680	681	(
I-control	681	688	control
I-control	689	694	group
I-control	694	695	)
O	695	696	.

O	697	700	The
O	701	709	infusion
O	710	713	was
O	714	721	stopped
O	722	723	1
O	724	728	hour
O	729	734	after
O	735	738	the
O	739	743	skin
O	744	751	closure
O	751	752	.

O	753	757	Pain
O	758	764	scores
O	765	768	and
O	769	778	analgesic
O	779	790	consumption
O	791	795	were
O	796	804	recorded
O	805	807	at
O	808	809	2
O	809	810	,
O	811	812	4
O	812	813	,
O	814	816	24
O	817	822	hours
O	822	823	,
O	824	827	and
O	828	832	then
O	833	838	daily
O	839	842	for
O	843	844	1
O	845	849	week
O	850	865	postoperatively
O	865	866	.

O	867	872	Three
O	873	879	months
O	880	885	later
O	885	886	,
O	887	895	patients
O	896	900	were
O	901	909	assessed
O	910	913	for
O	914	918	PPSP
O	919	922	and
O	923	932	secondary
O	933	945	hyperalgesia
O	945	946	.

B-iv-bin-abs	947	950	Two
O	951	952	(
B-iv-bin-percent	952	954	11
I-iv-bin-percent	954	955	.
I-iv-bin-percent	955	956	8
I-iv-bin-percent	956	957	%
O	957	958	)
O	959	967	patients
O	968	970	in
O	971	974	the
O	975	984	lidocaine
O	985	990	group
O	991	994	and
B-cv-bin-abs	995	996	9
O	997	998	(
B-cv-bin-percent	998	1000	47
I-cv-bin-percent	1000	1001	.
I-cv-bin-percent	1001	1002	4
I-cv-bin-percent	1002	1003	%
O	1003	1004	)
O	1005	1013	patients
O	1014	1016	in
O	1017	1020	the
O	1021	1028	control
O	1029	1034	group
O	1035	1043	reported
B-outcome	1044	1048	PPSP
I-outcome	1049	1051	at
I-outcome	1052	1053	3
I-outcome	1054	1060	months
I-outcome	1061	1067	follow
I-outcome	1067	1068	-
I-outcome	1068	1070	up
O	1071	1072	(
O	1072	1073	P
O	1073	1074	=
O	1074	1075	0
O	1075	1076	.
O	1076	1079	031
O	1079	1080	)
O	1080	1081	.

O	1082	1088	McGill
O	1089	1093	Pain
O	1094	1107	Questionnaire
O	1108	1116	revealed
O	1117	1124	greater
O	1125	1132	present
B-outcome	1133	1137	pain
I-outcome	1138	1147	intensity
I-outcome	1147	1148	-
I-outcome	1148	1154	visual
I-outcome	1155	1161	analog
I-outcome	1162	1167	scale
O	1168	1170	in
O	1171	1174	the
O	1175	1182	control
O	1183	1188	group
O	1189	1190	(
B-iv-cont-mean	1190	1192	14
I-iv-cont-mean	1192	1193	.
I-iv-cont-mean	1193	1194	6
O	1195	1196	±
B-iv-cont-sd	1197	1199	22
I-iv-cont-sd	1199	1200	.
I-iv-cont-sd	1200	1201	5
O	1202	1204	vs
O	1204	1205	.
B-cv-cont-mean	1206	1207	2
I-cv-cont-mean	1207	1208	.
I-cv-cont-mean	1208	1209	6
O	1210	1211	±
B-cv-cont-sd	1212	1213	7
I-cv-cont-sd	1213	1214	.
I-cv-cont-sd	1214	1215	5
O	1215	1216	;
O	1217	1218	P
O	1218	1219	=
O	1219	1220	0
O	1220	1221	.
O	1221	1224	025
O	1224	1225	)
O	1225	1226	.

B-outcome	1227	1236	Secondary
I-outcome	1237	1249	hyperalgesia
O	1250	1251	(
B-outcome	1251	1255	area
I-outcome	1256	1258	of
I-outcome	1259	1271	hyperalgesia
I-outcome	1271	1272	/
I-outcome	1272	1278	length
I-outcome	1279	1281	of
I-outcome	1282	1290	surgical
I-outcome	1291	1299	incision
O	1299	1300	)
O	1301	1304	was
O	1305	1318	significantly
O	1319	1323	less
O	1324	1326	in
O	1327	1330	the
O	1331	1340	lidocaine
O	1341	1346	group
O	1347	1355	compared
O	1356	1360	with
O	1361	1368	control
O	1369	1374	group
O	1375	1376	(
B-iv-cont-mean	1376	1377	0
I-iv-cont-mean	1377	1378	.
I-iv-cont-mean	1378	1379	2
O	1380	1381	±
B-iv-cont-sd	1382	1383	0
I-iv-cont-sd	1383	1384	.
I-iv-cont-sd	1384	1385	8
O	1386	1388	vs
O	1388	1389	.
B-cv-cont-mean	1390	1391	3
I-cv-cont-mean	1391	1392	.
I-cv-cont-mean	1392	1393	2
O	1394	1395	±
B-cv-cont-sd	1396	1397	4
I-cv-cont-sd	1397	1398	.
I-cv-cont-sd	1398	1399	5
I-cv-cont-sd	1400	1402	cm
O	1402	1403	;
O	1404	1405	P
O	1405	1406	=
O	1406	1407	0
O	1407	1408	.
O	1408	1411	002
O	1411	1412	)
O	1412	1413	.

O	1414	1417	The
O	1418	1419	2
O	1420	1426	groups
O	1427	1431	were
O	1432	1439	similar
O	1440	1442	in
O	1443	1448	terms
O	1449	1451	of
B-outcome	1452	1461	analgesic
I-outcome	1462	1473	consumption
O	1474	1480	during
O	1481	1484	the
O	1485	1490	early
O	1491	1504	postoperative
O	1505	1511	period
O	1511	1512	.

O	1513	1524	Intravenous
O	1525	1538	perioperative
O	1539	1548	lidocaine
O	1549	1558	decreases
O	1559	1562	the
B-outcome	1563	1572	incidence
I-outcome	1573	1576	and
I-outcome	1577	1585	severity
I-outcome	1586	1588	of
I-outcome	1589	1593	PPSP
O	1594	1599	after
O	1600	1606	breast
O	1607	1613	cancer
O	1614	1621	surgery
O	1621	1622	.

O	1623	1633	Prevention
O	1634	1636	of
O	1637	1640	the
O	1641	1650	induction
O	1651	1653	of
O	1654	1661	central
O	1662	1674	hyperalgesia
O	1675	1677	is
O	1678	1679	a
O	1680	1689	potential
O	1690	1699	mechanism
O	1699	1700	.
